leisure time -WSS

leisure time

author：focus 2025-08-28 08:39:36 - browse：698

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A biotech analyst on neuroscience, placebo effect, not over

focus

WSS

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

'Null' research findings aren't empty of meaning. Let's publish them

Emergent cuts jobs, executive role in business shake

Wegovy trial has doctors encouraged over new possibilities

Study links childhood stress with decline in older age

entertainment

leisure time

explore

Supreme Court strikes down use of affirmative action

Group behind ProMed defends move to subscription

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How to ethically and practically extend health care to all

Apple is now the first public company to be valued at $3 trillion

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

American woman, child freed after being kidnapped in Haiti last month

Hollywood unions extend contract negotiations for actors

Wegovy’s successful heart trial raises vital question about weight loss

knowledge

CDC recommends RSV monoclonal antibody for infants

What to know about Virgin Galactic's 1st mission taking paying customers to space

Drastic changes should bring profitability, startup health insurers say

FDA scientists endorse Pfizer/BioNTech Covid

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

2 officers injured in shooting in Orlando, police say

explore

focus

focus

focus